412 related articles for article (PubMed ID: 38260445)
21. Broadening the horizon: Integrative pharmacophore-based and cheminformatics screening of novel chemical modulators of mitochondria ATP synthase towards interventive Alzheimer's disease therapy.
Emmanuel IA; Olotu F; Agoni C; Soliman MES
Med Hypotheses; 2019 Sep; 130():109277. PubMed ID: 31383337
[TBL] [Abstract][Full Text] [Related]
22. In search of allosteric modulators of a7-nAChR by solvent density guided virtual screening.
Dey R; Chen L
J Biomol Struct Dyn; 2011 Apr; 28(5):695-715. PubMed ID: 21294583
[TBL] [Abstract][Full Text] [Related]
23. Modern Computational Strategies for Designing Drugs to Curb Human Diseases: A Prospect.
Dar KB; Bhat AH; Amin S; Hamid R; Anees S; Anjum S; Reshi BA; Zargar MA; Masood A; Ganie SA
Curr Top Med Chem; 2018; 18(31):2702-2719. PubMed ID: 30659543
[TBL] [Abstract][Full Text] [Related]
24. Regulation of phosphorylation pathways by p21 GTPases. The p21 Ras-related Rho subfamily and its role in phosphorylation signalling pathways.
Lim L; Manser E; Leung T; Hall C
Eur J Biochem; 1996 Dec; 242(2):171-85. PubMed ID: 8973630
[TBL] [Abstract][Full Text] [Related]
25. In silico identification and pharmacological evaluation of novel endocrine disrupting chemicals that act via the ligand-binding domain of the estrogen receptor α.
McRobb FM; Kufareva I; Abagyan R
Toxicol Sci; 2014 Sep; 141(1):188-97. PubMed ID: 24928891
[TBL] [Abstract][Full Text] [Related]
26. Activation of Rho Family GTPases by Small Molecules.
Palsuledesai CC; Surviladze Z; Waller A; Miscioscia TF; Guo Y; Wu Y; Strouse J; Romero E; Salas VM; Curpan R; Young S; Carter M; Foutz T; Galochkina Z; Ames H; Haynes MK; Edwards BS; Nicolotti O; Luo L; Ursu O; Bologa CG; Oprea TI; Wandinger-Ness A; Sklar LA
ACS Chem Biol; 2018 Jun; 13(6):1514-1524. PubMed ID: 29746086
[TBL] [Abstract][Full Text] [Related]
27. Ras-related GTPases and the cytoskeleton.
Hall A
Mol Biol Cell; 1992 May; 3(5):475-9. PubMed ID: 1611153
[TBL] [Abstract][Full Text] [Related]
28. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
Mishra V; Pathak C
J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
[TBL] [Abstract][Full Text] [Related]
29. Characterisation of the nucleotide exchange factor ITSN1L: evidence for a kinetic discrimination of GEF-stimulated nucleotide release from Cdc42.
Kintscher C; Groemping Y
J Mol Biol; 2009 Mar; 387(2):270-83. PubMed ID: 19356586
[TBL] [Abstract][Full Text] [Related]
30. Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity.
Zins K; Gunawardhana S; Lucas T; Abraham D; Aharinejad S
J Transl Med; 2013 Nov; 11():295. PubMed ID: 24279335
[TBL] [Abstract][Full Text] [Related]
31. Discovery of high affinity ligands for β2-adrenergic receptor through pharmacophore-based high-throughput virtual screening and docking.
Yakar R; Akten ED
J Mol Graph Model; 2014 Sep; 53():148-160. PubMed ID: 25137647
[TBL] [Abstract][Full Text] [Related]
32. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
Foffi G; Pastore A; Piazza F; Temussi PA
Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
[TBL] [Abstract][Full Text] [Related]
33. Targeting the Dbl and dock-family RhoGEFs: a yeast-based assay to identify cell-active inhibitors of Rho-controlled pathways.
Blangy A; Fort P
Enzymes; 2013; 33 Pt A():169-91. PubMed ID: 25033805
[TBL] [Abstract][Full Text] [Related]
34. A Cdc42 mutant specifically activated by intersectin.
Smith WJ; Hamel B; Yohe ME; Sondek J; Cerione RA; Snyder JT
Biochemistry; 2005 Oct; 44(40):13282-90. PubMed ID: 16201754
[TBL] [Abstract][Full Text] [Related]
35. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
Zaka M; Abbasi BH; Durdagi S
J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
[TBL] [Abstract][Full Text] [Related]
36. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
[TBL] [Abstract][Full Text] [Related]
37. Molecular network and chemical fragment-based characteristics of medicinal herbs with cold and hot properties from Chinese medicine.
Liang F; Li L; Wang M; Niu X; Zhan J; He X; Yu C; Jiang M; Lu A
J Ethnopharmacol; 2013 Jul; 148(3):770-9. PubMed ID: 23702041
[TBL] [Abstract][Full Text] [Related]
38. Proposing novel TNFα direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline.
Zaka M; Abbasi BH; Durdagi S
J Mol Graph Model; 2018 Oct; 85():111-121. PubMed ID: 30149308
[TBL] [Abstract][Full Text] [Related]
39. Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5.
Bian Y; Feng Z; Yang P; Xie XQ
AAPS J; 2017 Jul; 19(4):1235-1248. PubMed ID: 28560482
[TBL] [Abstract][Full Text] [Related]
40. Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases.
Oprea TI; Sklar LA; Agola JO; Guo Y; Silberberg M; Roxby J; Vestling A; Romero E; Surviladze Z; Murray-Krezan C; Waller A; Ursu O; Hudson LG; Wandinger-Ness A
PLoS One; 2015; 10(11):e0142182. PubMed ID: 26558612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
